EVOTF (Evotec SE) Institutional Ownership: 0.01% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVOTF Evotec SE EVOTF
61 GF Score
Price $6.69
GF Value $14.54
! 5 Warning Signs
View Full Analysis

What is Evotec SE Institutional Ownership?

Evotec SE EVOTF 61 Institutional Ownership is 0.01% as of Jul. 17, 2026. GuruFocus rates EVOTF with a GF Score™ of 61/100 and a GF Value™ of $14.54. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Evotec SE's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Evotec SE's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Evotec SE's Float Percentage Of Total Shares Outstanding is 99.83%.

Evotec SE Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Evotec SE's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Institutional Ownership Chart

Evotec SE Historical Data

The historical data trend for Evotec SE can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 18.77 19.29 20.18 21.68 21.54 21.57 21.05 21.79 21.66 20.92
EVOTF
61GF Score
Evotec SE EVOTF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.01% mean?
Evotec SE (EVOTF) has a Institutional Ownership of 0.01% as of Jul. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Evotec SE and its competitors.
Is Evotec SE's Institutional Ownership too high?
Evotec SE's current Institutional Ownership is 0.01%. Overall, Evotec SE has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Institutional Ownership compare to ZTS and UTHR?
Evotec SE's Institutional Ownership of 0.01% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Evotec SE and its competitors. Evotec SE's current Institutional Ownership is 0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (EVOTF) has a current Institutional Ownership of 0.01%. The stock's GF Value™ is $14.54, compared to a current price of $6.69 — trading 54% below its estimated fair value. The current Institutional Ownership is 0.01%. Evotec SE's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Evotec SE (EVOTF), the current Institutional Ownership is 0.01% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (EVOTF) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of $6.69 is trading 54% below its estimated GF Value™ of $14.54.

Key valuation signals for EVOTF:

  • Institutional Ownership: 0.01%
  • GF Value™: $14.54 vs. price of $6.69 (54% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the EVOTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
61GF Score

Get the complete analysis for EVOTF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price
$14.54
GF Value